In addition, we report that peroral treatment with L. reuteri reduces the bacterial load in MLNs and the expression of pro-inflammatory cytokines during colitis, in parallel with improved responses of conventional DCs and Foxp3+ T cells. The gene discussed is FOXP3; the disease is colitis.